IL13 and asthma: In clinical studies, anti-TSLP Ab treatment was shown to suppress asthma exacerbation in patients with severe asthma, [51] inhibit eosinophilic inflammation in the airway, and to decrease the concentrations of IL-5 and IL-13 in serum [15].